Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 1:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–39 of 39 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cariprazine Clear all

Conditions: Autism Spectrum Disorder
Interventions: Cariprazine, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 34
States / cities: Anaheim, California • Imperial, California • Orange, California + 28 more

Conditions: Bipolar Disorder
Interventions: Cariprazine (RGH-188), Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Bipolar Disorder, Depression
Interventions: Cariprazine, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 42
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 37 more

Conditions: Bipolar I Disorder
Interventions: Cariprazine; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 24
States / cities: Springdale, Arkansas • Carson, California • Cerritos, California + 20 more

Conditions: Schizophrenia
Interventions: Cariprazine, Risperidone/Moxifloxacin; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Glendale, California • Long Beach, California • Willingboro, New Jersey + 1 more

Conditions: Schizophrenia
Interventions: Cariprazine, Placebo; Drug
Lead sponsor: Gedeon Richter Plc.; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 9
States / cities: Culver City, California • Atlanta, Georgia • Bloomfield Hills, Michigan + 5 more

Conditions: Unipolar Depression, Bipolar Depression
Interventions: Vortioxetine, Cariprazine (Augmentation Phase); Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Major Depressive Disorder
Interventions: Cariprazine, Placebo, Antidepressant Therapy (ADT); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 752 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 58
States / cities: Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 50 more

Conditions: Opioid-use Disorder, Cocaine Use Disorder
Interventions: Cariprazine 1.5 MG, Placebo; Drug
Lead sponsor: Kyle Kampman; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Major Depressive Disorder
Interventions: Placebo, Cariprazine; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 819 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 39
States / cities: Garden Grove, California • National City, California • Oceanside, California + 34 more

Conditions: Bipolar Depression
Interventions: Cariprazine; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Major Depressive Disorder
Interventions: Cariprazine, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 759 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 65
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 59 more

Conditions: Schizophrenia
Interventions: Cariprazine; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 752 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 39
States / cities: Little Rock, Arkansas • Springdale, Arkansas • Carson, California + 30 more

Conditions: Major Depressive Disorder
Interventions: Cariprazine, Antidepressant Therapy (ADT); Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 442 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 88
States / cities: Tucson, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 74 more

Conditions: Generalized Anxiety Disorder
Interventions: Cariprazine 0.75 mg/day, Cariprazine 1.5 mg/day, Cariprazine 3.0 mg/day, Placebo; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 36
States / cities: Little Rock, Arkansas • Colton, California • Costa Mesa, California + 29 more

Search by objective public record fields.

Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD

Study Evaluating Cariprazine (RGH-188) in the Treatment of Patients With Acute Mania

Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder

Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder

Effects of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia

Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia

RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)

The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

Cariprazine for Comorbid Cocaine and Opioid Use Disorder

Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder

Dopamine D3 Receptor Occupancy in Bipolar Depression

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

Long-term Study of Cariprazine in Patients With Schizophrenia

Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder

A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone